Supplementary Tables S1-S4 and Supplementary Figures S1-S6 from Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance

Le résumé fourni par la source

Supplementary Table S1 - Therapeutic antibody induced EGFR ECR mutations; Supplementary Table S2 - Mean SPR KD values for binding of wild type (WT) and cetuximab resistance variants of sEGFR to immobilized Fab fragments from cetuximab (FabC225) and necitumumab (Fab11F8) and to EGF; Supplementary Table S3 - Crystallographic data collection and refinement statistics; Supplementary Table S4 - Changes in experimental binding and DSC4.1 computed energy terms for interaction of cetuximab (C225) and necitumumab (11F8) with wild type and epitope mutated EGFR variants; Supplementary Figure S1 - Binding of necitumumab and cetuximab to LK2 and HELA cells; Supplementary Figure S2 - Electron density near R468 in sEGFRd3-S468R/Fab11F8 structure; Supplementary Figure S3 - Comparison of the paratopes of necitumumab and panitumumab; Supplementary Figure S4 - Necitumumab exhibits structural plasticity in binding to sEGFRd3-S468R; Supplementary Figure S5 - Location of the epitope substitutions in the experimental test set and evaluation of the side chain conformations modeled with DSC4.1; Supplementary Figure S6 - CDR dynamics for necitumumab and cetuximab when bound to three cetuximab resistance variants, evaluated by MD simulations

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.